<?xml version="1.0" encoding="UTF-8"?>
<p>Emerging data suggest that provision of gender-affirming care may reduce HIV-related risk [
 <xref rid="pmed.1002422.ref051" ref-type="bibr">51</xref>] and improve engagement in the HIV prevention and care continuum [
 <xref rid="pmed.1002422.ref052" ref-type="bibr">52</xref>,
 <xref rid="pmed.1002422.ref053" ref-type="bibr">53</xref>] for transgender women. Testing interventions among transgender women in sub-Saharan Africa and ensuring that the results are utilized will be critical to ensuring that transgender women in the region are not left behind as countries implement their national HIV plans. In particular, as many countries scale up access to PrEP, important questions of acceptability [
 <xref rid="pmed.1002422.ref054" ref-type="bibr">54</xref>], adherence [
 <xref rid="pmed.1002422.ref055" ref-type="bibr">55</xref>], and potential drugâ€“drug interactions with feminizing hormone therapies [
 <xref rid="pmed.1002422.ref056" ref-type="bibr">56</xref>] must be addressed to facilitate engagement of transgender women.
</p>
